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Abstract: To determine whether conversion from cyclosporin A (CsA)
to tacrolimus (TAC)-based immunosuppressive therapy is safe and
might lead to improvement in the clinical side effect profile we studied
55 cardiac allograft recipients. Ten stable patients were electively con-
verted (0.2–1.5 yr after transplantation; group I) and 45 patients were
converted on indication (0.5–14 yr after transplantation; group II).
We studied blood pressure, cholesterol level and renal function in all
patients. To unravel the mechanisms by which CsA may exert its toxic
effects and to evaluate whether conversion is associated with immune
activation, we analyzed the transforming growth factor (TGF)-1 sys-
tem and intragraft interleukin (IL)-2 and IL-15 mRNA expression by
real-time reverse transcription-polymerase chain reaction (RT-PCR)
and quantitative flow cytometry in the selectively converted patients
(group I).
Conversion did not result in immune activation as no clinical, histolog-
ical or molecular signs of immune activation (increased intragraft IL-2
and IL-15 messenger RNA (mRNA) expression) leading to rejection
were found. It did not improve renal function neither in patient group
I nor in patient group II. However, after conversion the blood pressure
decreased (group I: systolic 15416 vs 14321 mmHg, p=0.03, dias-
tolic: 9911 vs 9011, p=0.02 and group II: systolic 15517 vs
14214, p0.001, diastolic: 9911 vs 918 mmHg, p0.001).
Likewise, the cholesterol levels improved (group I: 6.60.5 vs 5.70.3
mmol/L, p=0.001 and group II: 7.11.7 vs 6.11.7 mmol/L, p=
0.001). When patients were treated with TAC the ongoing rejections
(n=4) resolved and gum hyperplasia disappeared (n=5). Conversion
was associated with a two-fold lower TGF-1 type I receptor expres-
sion on peripheral lymphocytes and monocytes (p=0.02 and p=0.002,
respectively).
Conversion from CsA to TAC results in improvement of blood pres-
sure and cholesterol levels and does not induce immune activation.
These beneficial effects were accompanied with lower TGF-1 type I
receptor expression.
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After the introduction of cyclosporin A (CsA) the
results of clinical heart transplantation significantly
improved. Therefore, most immunosuppressive
regimens are CsA based (1). CsA affects T-cell
function at the level of messenger RNA (mRNA)
transcription of various cytokines, and in particu-
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lar of interleukin (IL)-2, which is critical for T-cell
proliferation and maturation. Unfortunately,
chronic treatment with CsA is associated with
CsA-specific side effects, e.g. hyperlipidemia, hy-
pertension, nephrotoxicity, hirsutism and gingivall
hypertrophy (2–6). The mechanisms by which CsA
treatment induces these side effects are not com-
pletely understood but it is known that CsA in-
creases mRNA levels for a number of genes
involved in cholesterol biosynthesis and hyperten-
sion (2, 7). Hypertension can be the result of an
abnormal sodium and water balance, endothelin-
mediated systemic vasoconstriction and impaired
vasodilatation secondary to reduction in nitric ox-
ide (6, 7). CsA can, by inducing lipid metabolism
disorders and hypertension, contribute to the de-
velopment of allograft vasculopathy, a complica-
tion affecting many cardiac allograft recipients at
the long term (1, 8). Nephrotoxicity is the third
important side effect related to chronic CsA treat-
ment. Two pathophysiologic mechanisms have
been postulated by which CsA may exert its
nephrotoxic effect. First, a vasomotor component
of afferent arteriolar constriction reducing the
glomerular perfusion, and second by replacement
of vascular smooth muscle cells by hyaline material
and the induction of interstitial fibrosis (9). Fur-
thermore, hirsutism and gum hypertrophy are
troublesome side effects commonly associated with
the use of CsA.
Several studies have demonstrated that CsA
stimulates cytokines, such as transforming growth
factor (TGF)-1 (10, 11). For instance, in CsA-
treated animals with chronic nephropathy an asso-
ciation was found between the characteristic
histological abnormalities in the kidney and in-
creased renal expression of TGF-1 (12, 13). Also
hypertension and transplant coronary artery dis-
ease have been associated with elevated TGF-1
levels (14, 15).
Primary treatment with tacrolimus (TAC), a
more recently introduced calcineurin inhibitor that
has a comparable mode of action to that of CsA,
has been shown to be more effective in the treat-
ment of ongoing rejection (16). Furthermore, both
single- and multi-center trials have shown that
treatment with TAC is accompanied with less hy-
perlipidemia and hypertension (17–19). In these
studies it appeared that TAC also has nephrotoxic
properties shown by renal dysfunction in TAC-
treated cardiac allograft recipients. However, con-
version studies from CsA to TAC in kidney
allograft recipients showed that TAC treatment
could significantly improve renal function (16, 20,
21).
The aim of this study was two-fold, first to
assess if the conversion from CsA to TAC is asso-
ciated both with immune activation and with im-
provement in CsA-related side effects in patients
with cardiac transplantation and second, to ana-
lyze the involvement of growth factors and cytoki-
nes as underlying mechanisms related to the
production of CsA toxic effects.
Material and methods
Patients
In 10 stable cardiac allograft recipients (9 males
and 1 female, mean age 51.8 yr, range 16–60 yr;
group I) time after transplantation 185 d (mean,
range 60–450 d), we evaluated the effect of conver-
sion from CsA to TAC. In these patients (group I)
we studied the clinical parameters: blood pressure,
renal function, and cholesterol level and the im-
munological parameters: intragraft IL-2 and IL-15
mRNA expression, and the TGF- system. Forty-
five cardiac allograft recipients (35 males and 10
females, mean age 48.8 yr, range 15–67 yr; group
II) were converted from CsA to TAC because of
hypertension (n=27), hypercholestemia (n=7),
ongoing acute rejection (n=4), gingival hyper-
plasia (n=5) and general malaise (n=2). Mean
time after transplantation of these patients was 5.5
yr (range 0.5–14 yr). Maintenance immunosup-
pressive therapy consisted of CsA, prednisolone in
all patients. In group II, 14 out of 45 patients also
received the immunosuppressant mycophenolate
mofetil.
All patients were on atorvastatin or pravastatin.
Hypertension (systolic150 mmHg and/or dias-
tolic100 mmHg) was treated by calcium-entry
blockers (first choice) or angiotensis-converting en-
zyme (ACE) inhibition (second choice). In some
patients, central working anti-hypertensive drugs
had to be added. Comparable anti-hypertensive
regimens were given to patients who were con-
verted early or at a later time point after transplan-
tation. Rejection was histologically diagnosed and
graded according to the criteria of the Interna-
tional Society for Heart and Lung Transplantation
(22). Anti-rejection therapy consisted of 1 g of
methylprednisolone i.v. for 3 consecutive days.
Frequently recurring or refractory rejection
episodes were treated with rabbit-ATG.
Real-time reverse transcription (RT)-PCR
We used the real-time reverse transcription-poly-
merase chain reaction (RT-PCR) technique to
quantify the amount of IL-2, IL-15, TGF-1
and glyceraldehyde phosphate dehydrogenase
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(GAPDH) mRNA expression in endomyocardial
biopsy taken before (n=15) and after conversion
(n=11) from patient group I. Messenger RNA
extraction and cDNA transcription were per-
formed as described in detail previously (23). The
real-time reverse transcriptase polymenase chain
reaction (RT-PCR) technique is based on the use
of the 5 nuclease activity of Taq DNA polymerase
to cleave a nonextendable dual-labeled fluorogenic
hybridization probe during the extension phase of
PCR. The probe is labeled with a reporter fluores-
cent dye at the 5 end and a quencer fluorescent
dye at the 3 end. Cleavage of the probe results in
an increase in reporter flourescence at each cycle.
Real-time PCR reactions are characterized by the
point during cycling when amplification of the
PCR product is first detected: the threshold cycle
(Ct) that is defined as the fractional cycle number
at which the flourescence generated by cleavage of
the probe passes above baseline. The target mes-
sage in endomyocard biopt (EMB) is quantified by
measuring Ct and by using a standard curve using
serial dilutions of a known amount of standard
RNA. The choice of primer and probe (IL-2, IL-
15) was defined using the primer express software
(PE Biosystems, Norwalk, CT, USA). Nucleotide
sequences for the oligonucleotide primers and
probes are the following: IL-2 sense primer: 5 TTT
GAA TGG AAT TAA TAA TTA CAA GAA
TCC 3, IL-2 anti-sense primer: 5 TTC TAG ACA
CTG AAG CTG TTT CAG TTC, IL-2 probe 5
CCA GGA TGC TCA CAT TTA AGT TTT
ACA TGC CC 3; IL-15 sense primer: 5 TGG
GTG AAT GTA ATA AGT GAT TTG AAA 3,
IL-15 anti-sense primer: 5 AAC TCC AAG AGA
AAG CAC TTC ATT G 3, IL-15 probe 5 TTT
ATA TAC GGA AAG TGA TGT TCA CCC
CAG TTG C 3. Pre-developed Taqman® PDAR
assays were used to measure TGF-1 and the
house keeping gene GAPDH concentrations (PE
Biosystems). GAPDH was used in each sample to
control sample-to-sample variations in mRNA
concentrations.
Five microliters of cDNA was added to 45 L of
PCR mixture containing 25 L of Universal PCR
Master Mix (PE Biosystems), 1 L of sense primer
(50 pmol), 1 L of anti-sense primer (50 pmol), 1
L of FAM labeled probe (10 pmol), and 17 L of
H2O. The PCR reaction was performed after a first
step of 2 min at 50°C and 10 min at 95°C by 40
cycles of 15 s at 95°C and 1 min at 58°C (IL-2,
IL-15) or 60°C (TGF-1, GAPDH) using the ABI
Prism 7700 sequence detector (PE Biosystems). All
experiments were performed in duplicate. The rela-
tive concentration of intragraft IL-2, IL-15 and
TGF-1 was divided by the relative concentration
of GAPDH. This represents the amount of target
mRNA transcript corrected for the amount of
mRNA used for RT and the efficacy of each
reaction.
Flow cytometry
Whole blood ethylenediaminetetracetic acid
(EDTA) samples were monitored for the presence
of monocytes (CD14 positive) and lymphocytes
(TCR positive). Surface markers were analyzed
by two-color cytometry using mAbs conjugated to
fluorescein isothiocyanate (FITC) or phycoerythrin
(PE). Quantitative flow cytometry was performed
as described previously (24). Briefly, cells were
stained with monoclonal antibodies directed to
CD14 (Immunotech, Marseille, France), as the
marker for monocytes, and WT31 (Immunotech)
as the marker for TCR positive cells, i.e. T-cells.
In both monocytes and T-cells, TGF- type I and
type II receptors were monitored. For TGF- type
I receptor a two-step staining was used. After the
first step with TGF- type I receptor antibodies (30
min at 4°C), the cells were washed three times with
2 mL Hanks-Balanced Salt Solution (HBSS)
(Gibco, Paisley, Scotland) supplemented with 1%
bovine serum albumin (BSA) (Sigma, St. Louis,
MO, USA) and 0.1% sodium azide, followed by
incubation with sheep-anti-rabbit IgG conjugated
with PE for 30 min at 4°C Sanver Tech (Santa
Cruz Biotechnology, Inc, Santa Cruz, CA, USA).
The antibody staining for TGF- type II receptor
was directly conjugated to PE Sanver Tech (Santa
Cruz Biotechnology, Inc, Santa Cruz, CA, USA).
The staining procedure was performed by incu-
bating 100 L whole blood with the above-men-
tioned monoclonal antibodies. After staining the
red blood cells were lysed with FACS lysing solu-
tion (B&D) during 10 min. Samples were centrifu-
gated and washed twice in cell Pack (TOA,
Hamburg, Germany). Flow cytometric analysis
was performed on a FACscan flow cytometer using
Cell Quest software (B&D). From each tube 10000
events in the gate were measured. To compare
different flow cytometric assays in time we cali-
brated the flow cytometer using specific Calibra-
tion Beads (Calibration Beads Quantum 1000,
Flow cytometer Standards Corp, San Jose, PR).
Each bead contains a known amount of
fluorochrome. The intensity of the flourescence is
converted to a standard curve by the Quick Cal
Program for Quantum Beads (B&D). The mean
flourescence is denoted as molecular equivalents of
soluble fluorochrome (MESF). Peripheral blood
cells from healthy subjects (n=12) served as con-
trols (4 males, mean age 30 yr, range 24–52 yr).
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Statistical analysis
Differences in distribution before and after conver-
sion were assessed using the paired two-way vari-
ance test (paired Student’s t-test). A level of
p0.05 was considered to indicate statistical
significance.
Results
Clinical data
We studied the effect of conversion from CsA to
TAC in two cohorts of cardiac allograft recipients.
Patients without overt CsA-related side effects
(n=10, group I) and those with CsA-related side
effects (n=45, group II). Clinical parameters stud-
ied in both cohorts included blood pressure, renal
function and lipid levels.
Before conversion the mean whole blood trough
CsA level for group I (no overt CsA-related side
effects, mean time after transplantation 185 d) was
25065 and for group II (patients with CsA-re-
lated side effects, mean time after transplantation
5.5 yr) was 13657 ng/mL. After conversion the
mean TAC trough level of these patients was
15.03.8 ng/mL (group I) and 8.82.7 ng/mL
(group II). Concurrent medication was not
changed.
Five out of 45 patients with overt CsA-related
side effects (group II) were converted to TAC
because of gum hypertrophy and 4 patients be-
cause of ongoing rejection episodes. The gum hy-
pertrophy disappeared and the ongoing rejection
resolved when patients received TAC. Conversion
to TAC did not lead to histologically proven acute
rejection episodes in any of the studied patients
without signs of rejection at time of conversion.
Table 1 summarizes the results of the clinical
parameters studied of the patients: blood pressure,
renal function and lipid levels. For patient group I,
converted to TAC within 2 yr after transplanta-
tion, and group II, patients who were switched to
TAC because of CsA induced side effects, no posi-
tive effect of the conversion on renal function was
found. The serum creatinine levels were compara-
ble before and after conversion group I: 14543
vs 12828 mol/L, p=0.10, and group II 162
56 vs 16068 mol/L, respectively, p=0.72. In
contrast, a significant improvement on both blood
pressure (systolic and diastolic) and total choles-
terol levels was observed. Already at 8 wk after
conversion, the systolic blood pressure of patient
group I decreased from 15416 to 14321
mmHg and the diastolic blood pressure from 99
11 to 9011 mmHg (p=0.03 and p=0.02, re-
spectively), and for group II from 15517 to
14214 mmHg (systolic) and 9911 to 918
mmHg (diastolic) (p0.001 and p0.001, respec-
tively). Total cholesterol levels improved for pa-
tient group I from 6.60.4 to 5.70.3 mmol/L
(p=0.001), and for patient group II from 7.11.7
to 6.11.7 mmol/L (p0.001).
Cytokine and cytokine receptor expression before and
after conversion
Intragraft mRNA expression of IL-2, IL-15 and
TGF-1 by real-time RT-PCR. We used the highly
Table 1. Effects of conversion from CsA to TAC on blood pressure, renal function and lipid levels
p value1After conversionBefore conversion
Patient group I (n=10)2
CsA tough level (ng/mL) 25065
TAC trough level (ng/mL) 15.03.8
Blood pressure
0.0315416 14321Systolic RR (mmHg)
Diastolic RR (mmHg) 9911 9011 0.02
Serum creatinine (mol/L) 14543 12828 0.10
5.70.3 0.0016.60.5Total cholesterol (mmol/L)
Patient group II (n=45)3
13657CsA trough level (ng/mL)
TAC trough level (ng/mL) 8.82.7
Blood pressure
1421415517 0.001Systolic RR (mmHg)
0.001Diastolic RR (mmHg) 9911 918
Serum creatinine (mol/L) 16256 16068 0.72
6.11.77.11.7Total cholesterol (mmol/L) 0.001
1 Paired Student’s t-test.
2 Patients (group I, described in detail in the Material and methods) who were converted from CsA to TAC within the first 2 post-operative years.
3 Patients (group II, described in detail in the Material and methods) who were converted from CsA to TAC because of CsA toxicity.
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Fig. 1. Messenger RNA expression levels of TGF-1 and
IL-15 measured in endomyocardial biopsies real-time RT-PCR
from patient group I before and after conversion from CsA to
TAC. No significant differences were found in intragraft
mRNA expression levels for TGF- and IL-15 before and after
conversion.
II receptor (Fig. 2). On both TCR  positive
lymphocytes and CD14 positive cells the mem-
brane bound expression of TGF-1 type I receptor
significantly decreased. Before conversion, during
CsA treatment the expression of the TGF-1 type
I receptor on TCR  positive lymphocytes was
MESF 97184947 (meanSD) which decreased
to MESF 64062886 after conversion to TAC,
and on CD14 positive monocytes from MESF
152636979 to MESF 80126181 (p=0.02 and
p=0.002, respectively).
Discussion
In the present study, we have analyzed the conse-
quences of conversion from CsA to TAC on both
clinical and immune parameters of cardiac allo-
graft recipients. Shortly after transplantation,
within 2 yr (patient group I) the conversion to
TAC resulted in improvement of blood pressure
and cholesterol levels. This improvement in the
studied clinical parameters was also seen in pa-
tients who were switched to the immunophilin
TAC because of severe CsA toxicity. Even, as long
as 14-yr post-transplant patients may benefit from
conversion from CsA to TAC concerning hyper-
tension, hypercholestemia and gum hyperplasia.
Furthermore, the ongoing rejections resolved when
patients were treated with TAC. These beneficial
effects were accompanied with decreased expres-
sion of TGF- type I receptor on peripheral
mononuclear blood cells. Furthermore, a change in
the immunosuppressive protocol did not lead to
immune activation, neither histological signs of
acute rejection nor increased IL-2 or IL-15 mRNA
expression in EMB were seen.
Hyperlipidemia, hypertension and renal failure
are very common following heart transplantation
and the prevalence increases with time after trans-
plantation (1). These complications are important
non-immunologic risk factors in allograft recipi-
ents. High lipid levels may contribute to the onset
and/or progression of chronic rejection, while renal
insufficiency has a high impact on the mortality of
the cardiac allograft recipients (1, 5). These and
other complications are often related to chronic
CsA treatment that can exert its adverse effects by
disturbed cytokine production (10, 11). Therefore,
the beneficial effects seen in our and other conver-
sion studies might be the result of restored physio-
logical levels of TGF-1, a cytokine known for its
role in CsA toxicity (12, 14, 17–19). Recently, we
could indeed show that TGF-1 plays a role in
renal insufficiency in our CsA-treated cardiac allo-
graft recipients as we found an association between
TGF-1 codon 10 genotypes and renal dysfunction
reproducible real-time RT-PCR to quantify intra-
graft IL-2, IL-15, and TGF-1 mRNA expression
in endomyocard biopt (EMB) from stable cardiac
allograft recipients (n=10, group I) before (n=
15) and after conversion at 8 wk (mean, n=11)
from CsA to TAC.
There was no difference in intragraft cytokine
mRNA expression levels before and after conver-
sion. Comparable intragraft TGF-1 and IL-15
mRNA levels were measured (Fig. 1). The expres-
sion of IL-2, the cytokine associated with immune
reactivity, was only detectable in 2/26 EMB. One
specimen was positive during CsA treatment and
one specimen during TAC treatment.
Peripheral expression of TGF-1 type I and II
receptors by quantitatie flow cytometry. To assess
the effects of immunosuppressive medication on
the expression level of TGF-1 receptors on pe-
ripheral T-lymphocytes (TCR  positive) and
monocytes (CD14 positive) we used quantitative
flow cytometry. The analysis was exclusively per-
formed on peripheral blood samples from patient
group I.
Only a few TCR  lymphocytes stained positive
for the type I and type II TGF-1 receptors, 2.1
2.2% and 2.22.7% (meanSD), respectively.
The proportion of CD14 positive cells with TGF-
1 type I receptors was 44.628.5% and with type
II receptors 8.77.2%. For TGF-1 type I and
type II receptors these percentages on TCR 
positive and CD14 positive peripheral blood cells
were not influenced by the conversion to TAC.
However, conversion did affect the expression level
of TGF-1 type I receptor and not of TGF-1 type
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(serum creatinine 250 mol/L) (25). In the
present study, no effect of conversion was seen on
the intragraft mRNA expression level of TGF-
(Fig. 1) as the activation of this particular cytokine
is regulated at the protein level (26). Therefore, a
possible relationship between TGF- expression
and CsA toxicity can be found by analyzing active
TGF-1 protein levels. In that prospect it is impor-
tant to study both the TGF- expression by par-
enchymal cells and graft infiltrating cells.
Cytokines act on target cells through high
affinity membrane receptors. The active form of
TGF-1 binds to the TGF- type I and type II
receptors, which are signaling mediators (26).
Nowadays, patients are often treated with the im-
munosuppressant TAC, a calcineurin inhibitor that
competes with TGF- type I receptor for FKBP12
interaction (26, 27). FKB12 is a binding protein for
TAC (i.e. FK506). Thus, association of FKBP12
with TGF- type I receptor decreases receptor
signaling. In the present conversion study from
CsA to TAC we confirmed that treatment with
TAC reduced TGF- type I receptor expression on
peripheral blood cells. Also primary treatment
with TAC is not associated with increased produc-
tion of TGF-1 (28, 29). These findings may ex-
plain why cardiac allograft recipients on a
TAC-based immunosuppressive regimen have less
hypertension and hyperlipidemia, and better renal
function than patients treated with CsA (17–19).
In our patient population, conversion from CsA
to TAC did resolve the ongoing rejections and
resulted in significant improvement of systolic and
diastolic blood pressure and lipid levels and the
gum hypertrophy disappeared even after years of
chronic CsA treatment. The beneficial effects of
replacement of CsA by TAC on plasma cholesterol
levels might be the result of shutting of the key
gene involved in cholesterol biosynthesis, i.e. sterol
regulatory element-binding protein (SREBP)-2 (2).
However, despite improved blood pressure the
conversion did not improve renal function reflect-
ing either comparable intrarenal vasoconstriction
based nephrotoxicity of both CsA and TAC lead-
ing to diminished glomerular filtration rate or
structural kidney damage induced by long-term
CsA therapy. Renal insufficiency induced by CsA
is characterized by interstitial fibrosis, tubular at-
rophy and glomerular vascular lesions (30).
We conclude that conversion from CsA to TAC
is of benefit for cardiac allograft recipients even for
patients who were on CsA for years. The change in
immunosuppressive regimen was associated with
decreased TGF-1 type I receptor expression on
peripheral mononuclear blood cells, suggestive for
the involvement of TGF-1 in CsA–related
complications.
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